In oncology, CRISPR is enabling next-generation CAR-T to combat cancer cells – Chimeric Antigen Receptor T-cell or CAR-T therapy is a newly developing immunotherapy that modifies a patient’s own T-cells to target and kill malignant cells while keeping healthy cells intact. This new type of therapy is also cheaper than other recently approved cancer immunotherapies. CART-T cancer immunotheraphy could generate a projected $433 billion per year in revenues with royalties to CRISPR companies, Samy said.

To help investors tap into these new technologies and potential capitalize on the growth potential of these innovations, Renato Leggi, Product Specialist for ARK Invest, highlighted the ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG), which provides “exposure to CRISPR, gene editing, therapeutics, agricultural biology and health care innovation,” according to ARK Invest.

Leggi argued that the disruptive innovation strategy can help provide investors with portfolio diversification, a source of alpha and a hedge for index-based strategies. The thematic investing in disruptive innovation offers a low correlation to traditional growth strategies and negative correlation to value strategies. Adding on to the diversification theme, a constant focus on secular changes and disruptive innovation can offer a portfolio hedge in a rapidly changing world and complement traditional strategies. Additionally, the actively managed ETF offers a top-down approach looks at secular trends and ecosystems to find attractive growth opportunities across sectors.

Financial advisors who are interested in learning more about a biotechnology growth opportunity can watch the webcast here on demand.